Bowel Preparation in Colonoscopy: Lactulose vs Polyethyleneglycol, Randomized Double-blind Comparative Clinical Trial, Multicenter Study.
| 대상 질환 | Colorectal Cancer Screening |
|---|---|
| 임상 단계 | 4상 |
| 스폰서 | Hospital Civil de Guadalajara |
| 상태 | 완료 |
| 참여자 수 | 449 명 |
| 중재(약물) | Bowel preparation before colonoscopy, Bowel preparation before colonoscopy |
| 시작일 | 2024년 7월 20일 |
| 완료일 | 2025년 7월 31일 |
| 결과 공개일 | 2026년 7월 28일 |
요약
The goal of this clinical trial it is to bowel the instestinal preparation with lactulose vs poliethylenglicol as better agent to have a quality colonoscopy and demostrate that lactulose is most efective, has a good tolerance and the patient would have a better satisfaction, so the question is: wich is the eficancy of lactulose in comparision with thepoliethylenglycol in the intestinal preparation for the colonoscopy?
Bowel Cleansing Was Assessed Using the Boston Bowel Preparation Scale (BBPS).
| Bowel Preparation With Lactulose Before de Colonoscopy | 7.21 ± 1.61 Score scale |
|---|---|
| Bowel Preparation With Plyethylenglycol Before the Colonoscopy | 7.08 ± 1.49 Score scale |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- CryoBalloon Ablation for Treatment of Duodenal Adenomas — Johns Hopkins University
- Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refract — Jennerex Biotherapeutics
- Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III — National Cancer Institute (NCI)
- Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps — National Cancer Institute (NCI)
- Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal — National Cancer Institute (NCI)
- Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating — National Cancer Institute (NCI)